We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
172 hedge funds and large institutions have $662M invested in ANI Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 72 increasing their positions, 25 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
309% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 11
188% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 25
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
61% more capital invested
Capital invested by funds: $411M → $662M (+$251M)
25% more funds holding
Funds holding: 138 → 172 (+34)
22% more call options, than puts
Call options by funds: $1.46M | Put options by funds: $1.2M
1.69% more ownership
Funds ownership: 59.4% → 61.09% (+1.7%)
Holders
172
Holders Change
+34
Holders Change %
+24.64%
% of All Funds
2.7%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
45
Increased
72
Reduced
25
Closed
11
Calls
$1.46M
Puts
$1.2M
Net Calls
+$258K
Net Calls Change
+$318K
Top Buyers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$22.8M |
| 2 |
RIM
Ranger Investment Management
Dallas,
Texas
|
+$14.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.6M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$8.82M |
| 5 |
BlackRock
New York
|
+$8.48M |
